The data contain confidential information concerning Medicare beneficiaries. Therefore, we do not have the authority to share them per the restrictions imposed by the Centers for Medicare and Medicaid Services. Requests may be sent to ResDAC (<https://www.resdac.org/>; <resdac@umn.edu>) in order to obtain the Medicare data.

Introduction {#sec001}
============

The beta blockers carvedilol, bisoprolol, and sustained-release metoprolol succinate have been shown to reduce readmissions and mortality for patients with heart failure with reduced ejection fraction (HFrEF). These findings have led to the use of beta blocker prescriptions at hospital discharge as an indicator of quality of care \[[@pone.0233161.ref001],[@pone.0233161.ref002]\]. However, the evidence for their benefit is based largely upon patients enrolled in randomized controlled trials (RCTs) and heart failure registries \[[@pone.0233161.ref003]--[@pone.0233161.ref006]\]. Participants in these studies were likely different from the typical patient hospitalized for HFrEF, potentially limiting the generalizability of these results. For example, only 25% of Medicare beneficiaries hospitalized with HFrEF would have met the inclusion criteria for the RCTs due to age, contraindications, or comorbidities \[[@pone.0233161.ref007]\]. Additional therapies such as eplerenone \[[@pone.0233161.ref008]\] and sacubitril/valsartan \[[@pone.0233161.ref009]\] have demonstrated effective reduction in mortality and readmissions, but sacubitril/valsartan had yet to experience meaningful uptake in its first 18 months of approval through the end of 2016 \[[@pone.0233161.ref010]\]. Beta blocker therapy, in addition to other therapies such as ACE-inhibitors, remain common pharmaceutical therapies for HFrEF in the general patient population. Therefore, we conducted a retrospective cohort study of the Medicare 5% random sample to determine the relative risk for heart failure (HF) readmission, all-cause readmission, and mortality associated with use of these evidence-based beta blockers among beneficiaries hospitalized for HFrEF.

Materials and methods {#sec002}
=====================

Study sample {#sec003}
------------

Using the 5% random sample of Medicare beneficiaries, we identified beneficiaries who: had an inpatient claim and were discharged alive with a primary discharge diagnosis of 428.2x (systolic heart failure) or 428.4x (combined systolic and diastolic heart failure) between 2007 and 2013, were living in the US for 365 days prior to hospital admission date, had continuous Medicare Part A, B, and D coverage for 365 days prior to hospital admission date, had continuous inclusion in the Medicare 5% sample for 365 days prior to hospital admission date, and were less than 110 years on hospital admission date. Follow up data after hospital discharge were collected through one year, with follow up data available through 2013. We conducted analyses with 30 days of follow up and with 365 days of follow up. We used the first eligible HFrEF hospitalization for each beneficiary as the index hospitalization, which was not necessarily an incident HFrEF hospitalization, and we excluded beneficiaries who were discharged to a skilled nursing facility (SNF) because medications are not generally billed separately during a SNF stay \[[@pone.0233161.ref011]\].

Beta blocker prescription fills {#sec004}
-------------------------------

Previous studies with registry populations have relied upon discharge prescriptions in the medical record \[[@pone.0233161.ref003]\]. However, discharge prescriptions may be an indicator of provider behavior rather than patient behavior. Therefore, we used a claim for filling a prescription for an evidence-based beta blocker for HFrEF as a proxy for taking an evidence-based beta blocker at least once within a year following hospitalization. Prescription fills for carvedilol, bisoprolol, or sustained-release metoprolol succinate were identified using Medicare Part D pharmacy claims. Beneficiaries were considered non-users until they had a claim for a prescription fill. Once a person had a claim for a prescription fill, they were considered a user for the remainder of follow up.

Outcomes {#sec005}
--------

The primary outcomes of interest in this study were: (1) time to HF readmission (defined as a hospitalization claim with a primary discharge diagnosis of HF, with or without indication of systolic function; see [S1 Methods](#pone.0233161.s001){ref-type="supplementary-material"}); (2) time to all-cause readmission; and (2) time to death. We used follow up at 30 days and 365 days as the time intervals of interest. Beneficiaries were censored if they lost fee-for-service coverage in Medicare, left the 5% national sample, or moved out of the 50 United States or Washington D.C. Death was considered to be a competing risk for readmission. All-cause mortality was collected from the Medicare beneficiary enrollment file that includes death dates reported by the Social Security Administration.

Covariates {#sec006}
----------

To account for potential confounding, we included demographics, healthcare utilization, comorbidities, use of other medications for HF, and year of HFrEF hospitalization in our multivariable-adjusted models. Demographic variables included age at hospital admission, sex, race (black, other, and white), US census region of residence (East North Central, East South Central, Middle Atlantic, Mountain, New England, Pacific, South Atlantic, West North Central, and West South Central), dual-eligibility for Medicare and Medicaid, and having a Medicare Part D subsidy. Healthcare utilization during the year prior to hospitalization was captured by whether the beneficiary had a prescription fill for a beta blocker (evidence-based beta blocker for HFrEF, other beta blocker, or none), was hospitalized for any cause, lived in a nursing home \[[@pone.0233161.ref012]\], or had a stay in a SNF. Comorbidities during the year prior to hospitalization included anemia, atrial fibrillation, COPD, the Charlson comorbidity index, depression, hypotension, liver disease, and malnutrition (see [S1 Methods](#pone.0233161.s001){ref-type="supplementary-material"} for specific definitions). Use of other medications for HF in the past year include ACEI/ARB use and diuretic use.

Statistical analysis {#sec007}
--------------------

First, we calculated summary statistics for each covariate for those that ever filled a prescription for an evidence-based beta blocker within 30 days and for those that filled a prescription for an evidence-based beta blocker after 30 days or never filled a prescription. Second, we fit a Fine and Gray \[[@pone.0233161.ref013]\] competing risk model for the readmission outcomes (HF and all-cause), in order to account for the important competing risks of mortality and other types of readmission (when HF readmission was the outcome). We fit a standard Cox proportional hazards model for mortality. Competing risk models allowed for comparisons of readmission outcomes after accounting for potential differences in follow up time due to a competing outcome between those who used beta blockers versus those who did not. Beta blocker use was modeled as a time-varying exposure. Beneficiaries were considered to be beta blocker users from the date of the first fill through the end of follow up. We allowed the risk ratio (RR) for beta blocker use to vary with time by using an interaction with a categorical variable for time post hospital discharge (0--3 days, 4--7 days, or \>= 8 days), in order to satisfy the proportional hazards assumption \[[@pone.0233161.ref014]\]. We reported the RRs for each of these time intervals.

We conducted four sensitivity analyses. First, we repeated the analysis for a subset of beneficiaries that had characteristics similar to an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) registry \[[@pone.0233161.ref003]\], which was limited to patients with HFrEF who were naive to beta blocker treatment (defined as not filling a prescription for any beta blocker in the year prior to HFrEF hospitalization), were at least 65 years of age, and were good candidates for beta blockers by excluding beneficiaries with either bradycardia or atrioventricular block (degree two or three) but without an accompanying pacemaker, had asthma, or had hypotension, all in the year prior to hospitalization for HFrEF, were discharged to hospice or against medical advice, had cardiogenic shock during the hospitalization for HFrEF, or were transferred to another acute care facility. Second, we conducted an analysis that excluded beneficiaries with any days of carvedilol, bisoprolol, or sustained-release metoprolol succinate available on the day of hospital admission according to Part D pharmacy claims for the beneficiary, in order to decrease the potential for exposure misclassification for participants who might have been taking beta blockers from a previous prescription immediately following discharge. Third, we repeated the analysis in a subset of participants who did not have history of a procedure code for an implanted cardiac device (pacemaker and/or defibrillator; see [S1 Methods](#pone.0233161.s001){ref-type="supplementary-material"} for codes used). Potential contraindications or variation in effects of beta blockers between those with and without an implanted cardiac device motivated this analysis. Fourth, we modified the exposure from "filled or not filled" to "filled carvedilol, filled bisoprolol, filled sustained-release metoprolol succinate, or not filled." The first fill for one of these beta blockers determined the exposure category in which the beneficiary remained during the rest of follow up, regardless of future beta blocker fills. This sensitivity analysis attempted to detect any variation in the associations between fills for specific beta blockers and the outcomes of interest. For all sensitivity analyses, we reported only the hazard ratios for the 8--30 or 8--365 day time period.

This study was approved by the University of Alabama at Birmingham Institutional Review Board and the Centers for Medicare and Medicaid Services Privacy Board.

Results {#sec008}
=======

These inclusion / exclusion criteria led to a final sample size of 12,127 beneficiaries hospitalized for HFrEF. Although our exclusion criteria were necessary to identify our target study population, they removed 80% of the identified HF hospitalizations from 2007 to 2013 among beneficiaries in our 5% random sample (see [S1 Table](#pone.0233161.s003){ref-type="supplementary-material"}). Many beneficiaries were excluded because the HF diagnosis code did not contain information on systolic function or indicated isolated diastolic dysfunction. The median(interquartile range \[IQR\]) days of follow up for the 365-day interval was 136(332) for HF readmission, 98(261) days for all-cause readmission, and 365(210) for mortality. By 365 days, 62% of beneficiaries were readmitted and 27% died. Forty-three percent of beneficiaries filled a prescription for an evidence-based beta blocker within 30 days of discharge. The median(IQR) time to prescription fill among those who filled a prescription for an evidence-based beta blocker within 30 days was 5(24) days. Summaries of demographics, healthcare utilization, comorbidities, potential contraindications, and year of hospitalization by whether the beneficiary filled a prescription for an evidence-based beta blocker within 30 days are shown in [Table 1](#pone.0233161.t001){ref-type="table"}.

10.1371/journal.pone.0233161.t001

###### Characteristics of medicare beneficiaries hospitalized for HFrEF by whether beneficiary filled a prescription for an evidence-based beta blocker within 30 days.

![](pone.0233161.t001){#pone.0233161.t001g}

  Variable                                                         Level                Filled prescription for beta blocker within 30 days (n = 5,164)   Did not fill prescription for beta blocker within 30 days (n = 6,963)
  ---------------------------------------------------------------- -------------------- ----------------------------------------------------------------- -----------------------------------------------------------------------
  Age at admission (years)[^a^](#t001fn001){ref-type="table-fn"}                        74.1 (12.1)                                                       75.8 (12.3)
  Race                                                             Black                889 (17.2)                                                        1002 (14.4)
                                                                   Other                322 (6.2)                                                         397 (5.7)
                                                                   White                3953 (76.5)                                                       5564 (79.9)
  Women                                                                                 2533 (49.1)                                                       3437 (49.4)
  Dual-eligible for Medicare and Medicaid                                               2112 (40.9)                                                       2547 (36.6)
  Medicare Part D subsidy                                                               2558 (49.5)                                                       3114 (44.7)
  US Census region                                                 East North Central   880 (17.0)                                                        1215 (17.4)
                                                                   East South Central   534 (10.3)                                                        731 (10.5)
                                                                   Middle Atlantic      644 (12.5)                                                        1054 (15.1)
                                                                   Mountain             195 (3.8)                                                         281 (4.0)
                                                                   New England          233 (4.5)                                                         334 (4.8)
                                                                   Pacific              533 (10.3)                                                        589 (8.5)
                                                                   South Atlantic       1002 (19.4)                                                       1344 (19.3)
                                                                   West North Central   454 (8.8)                                                         487 (7.0)
                                                                   West South Central   689 (13.3)                                                        928 (13.3)
  Anemia                                                                                2598 (50.3)                                                       3929 (56.4)
  Asthma                                                                                801 (15.5)                                                        1103 (15.8)
  Atrial fibrillation                                                                   2132 (41.3)                                                       3415 (49.0)
  Atrioventricular block (2nd or 3rd degree)                                            36 (0.7)                                                          41 (0.6)
  Beta blocker use at baseline                                     Evidence-based       3305 (64.0)                                                       2907 (41.7)
                                                                   None                 1165 (22.6)                                                       1851 (26.6)
                                                                   Other beta blocker   694 (13.4)                                                        2205 (31.7)
  ACEI/ARB use                                                                          3690 (71.5)                                                       4666 (67.0)
  Diuretic use                                                                          3879 (75.1)                                                       5264 (75.6)
  Bradycardia                                                                           55 (1.1)                                                          127 (1.8)
  COPD                                                                                  2334 (45.2)                                                       3425 (49.2)
  Cardiogenic shock                                                                     41 (0.8)                                                          57 (0.8)
  Charlson comorbidity index                                       0                    1914 (37.1)                                                       2704 (38.8)
                                                                   1--3                 723 (14.0)                                                        827 (11.9)
                                                                   \>=4                 2527 (48.9)                                                       3432 (49.3)
  Depression                                                                            1012 (19.6)                                                       1431 (20.6)
  Discharged against medical advice                                                     26 (0.5)                                                          42 (0.6)
  Discharged to hospice                                                                 50 (1.0)                                                          449 (6.4)
  Hospitalization during baseline                                                       1273 (24.7)                                                       2088 (30.0)
  Hypotension                                                                           968 (18.7)                                                        1465 (21.0)
  Liver disease                                                                         225 (4.4)                                                         344 (4.9)
  Malnutrition                                                                          277 (5.4)                                                         545 (7.8)
  Nursing home residence                                                                283 (5.5)                                                         588 (8.4)
  Skilled nursing facility stay                                                         473 (9.2)                                                         959 (13.8)
  Year of hospitalization                                          2007                 279 (5.4)                                                         336 (4.8)
                                                                   2008                 741 (14.3)                                                        901 (12.9)
                                                                   2009                 776 (15.0)                                                        1047 (15.0)
                                                                   2010                 853 (16.5)                                                        1115 (16.0)
                                                                   2011                 827 (16.0)                                                        1161 (16.7)
                                                                   2012                 815 (15.8)                                                        1172 (16.8)
                                                                   2013                 873 (16.9)                                                        1231 (17.7)

^a^mean (standard deviation)

Multivariable-adjusted RRs for readmission and mortality are shown in [Table 2](#pone.0233161.t002){ref-type="table"}/[Fig 1](#pone.0233161.g001){ref-type="fig"}. In fully adjusted models, filling a prescription for an evidence-based beta blocker was associated with an approximately 20% lower risk of an HF readmission from 8--30 and 8--365 days post discharge. However, filling a prescription for an evidence-based beta blocker was not significantly associated with all-cause readmission from 8--30 or 8--365 days, with RRs close to the null value of 1. Filling a prescription for a beta blocker was associated with a 32% lower mortality from 8--30 days and a 35% lower mortality from 8--365 days post discharge.

![Risk ratios (RRs) and 95% confidence intervals for filling a prescription for carvedilol, bisoprolol, or sustained-release metoprolol succinate after discharge from a hospitalization for heart failure with reduced ejection fraction (HFrEF).\
Models were adjusted for age at admission, sex, race, US census region, year of HFrEF hospitalization, as well as several variables assessed during the year prior to hospitalization: type of beta blocker use (evidence-based beta blocker for HFrEF, any other beta blocker, or none), ACEI/ARB use, diuretic use, dual-eligibility, Medicare Part D subsidy, nursing home residence, atrial fibrillation, malnutrition, liver disease, anemia, depression, COPD, Charlson comorbidity index, hospitalization, and a skilled nursing facility (SNF) stay. An RR of 1 indicated no significant association. Although confidence intervals are plotted, the intervals are so narrow that some are hard to see.](pone.0233161.g001){#pone.0233161.g001}

10.1371/journal.pone.0233161.t002

###### Risk ratios (RRs) and 95% confidence intervals for filling a prescription for carvedilol, bisoprolol, or sustained-release metoprolol succinate after discharge from a hospitalization for heart failure with reduced ejection fraction (HFrEF).

![](pone.0233161.t002){#pone.0233161.t002g}

  Outcome[^a^](#t002fn001){ref-type="table-fn"}   Time period within follow up   30 days             365 days
  ----------------------------------------------- ------------------------------ ------------------- -------------------
  HF readmission                                  0--3 days                      0.92 (0.91--0.93)   0.89 (0.87--0.90)
  HF readmission                                  4--7 days                      0.97 (0.96--0.98)   0.95 (0.93--0.96)
  HF readmission                                  \>7 days                       0.83 (0.81--0.84)   0.79 (0.76--0.82)
  All-cause readmission                           0--3 days                      1.08 (0.84--1.39)   1.08 (0.84--1.39)
  All-cause readmission                           4--7 days                      1.08 (0.88--1.32)   1.05 (0.86--1.28)
  All-cause readmission                           \>7 days                       0.97 (0.88--1.08)   1.02 (0.97--1.07)
  Mortality                                       0--3 days                      0.17 (0.08--0.37)   0.17 (0.08--0.37)
  Mortality                                       4--7 days                      0.38 (0.22--0.68)   0.37 (0.21--0.66)
  Mortality                                       \>7 days                       0.69 (0.55--0.86)   0.65 (0.60--0.71)

^a^Models were adjusted for age at admission, sex, race, US census region, year of HFrEF hospitalization, as well as several variables assessed during the year prior to hospitalization: type of beta blocker use (evidence-based beta blocker for HFrEF, any other beta blocker, or none), ACEI/ARB use, diuretic use, dual-eligibility, Medicare Part D subsidy, nursing home residence, atrial fibrillation, malnutrition, liver disease, anemia, depression, COPD, Charlson comorbidity index, hospitalization, and a skilled nursing facility (SNF) stay. An RR of 1 indicated no significant association

[S2 Table](#pone.0233161.s004){ref-type="supplementary-material"} shows the sample characteristics for the sensitivity analysis of the subsample similar to OPTIMIZE-HF that excluded 10,514 beneficiaries, and [S3 Table](#pone.0233161.s005){ref-type="supplementary-material"} shows the multivariable-adjusted RRs for this subsample. In the subsample similar to OPTIMIZE-HF, beta blocker use was associated with a 5% lower risk of HF readmission from 8--30 days, but was not significantly associated with HF readmission from 8--365 days, with a RR of 1. Similar to the main analysis, the association between beta blocker use and all-cause readmission was not statistically significant from 8--30 or 8--365 days. The association with mortality was not statistically significant from 8--30 days with a wide confidence interval, likely due to a smaller number of events. However, beta blocker use was associated with a statistically significant 36% lower mortality at 8--365 days post discharge in the sample similar to OPTIMIZE-HF.

The sensitivity analysis that excluded participants with any days of an evidence-based beta blocker available upon hospital admission ([S4 Table](#pone.0233161.s006){ref-type="supplementary-material"}) produced estimates of the association between beta blocker use and the outcomes that were similar to the main analysis. The sensitivity analysis that excluded participants with an implanted cardiac device produced estimates almost identical to the main analysis as well ([S5 Table](#pone.0233161.s007){ref-type="supplementary-material"}). The final sensitivity analysis, which specified which particular evidence-based beta blocker was filled (carvedilol, bisoprolol, metoprolol succinate, or none), showed nearly identical RRs for each specific beta blocker vs. no fill ([S1 Fig](#pone.0233161.s002){ref-type="supplementary-material"}). The confidence intervals for the RRs for bisoprolol fill vs. no fill were sometimes much larger than for the other beta blockers, indicating fewer beneficiaries filling prescriptions for bisoprolol compared to the carvedilol or sustained-release metoprolol succinate.

Discussion {#sec009}
==========

We identified a cohort of Medicare beneficiaries hospitalized with a primary discharge diagnosis of HFrEF, with the goal of comparing readmission rates among those who filled a prescription for an evidence-based beta blocker for HFrEF and those who did not. We used prescription fill claims as a proxy for beta blocker use. We found that beta blocker use was associated with lower risk of HF readmission at 30 and 365 days, after accounting for the competing risks of readmissions for other causes and mortality. We found that the 30-day and 365-day all-cause readmission rates were similar between beneficiaries who filled a prescription for an evidence-based beta blocker and those who did not, after accounting for the increased mortality among those that did not fill a prescription. Finally, mortality was approximately 30%--35% lower among those that filled a prescription for an evidence-based beta blocker.

In contrast to OPTIMIZE-HF, our main analysis did not find evidence of an association between beta blocker use and all-cause readmission, after accounting for the increased mortality among those that did not use a beta blocker. One explanation for the differences could be that Hernandez et al. (2009) \[[@pone.0233161.ref003]\] assessed use of any beta blocker, as opposed to evidence-based beta blockers for HFrEF. We observed similar 1-year readmission rates (64% in OPTIMIZE-HF vs. 62% in our study) and mortality rates (33% in OPTIMIZE-HF vs. 27% in our study). When we restricted our study sample to beneficiaries that met exclusion criteria similar to OPTIMIZE-HF, the estimated RRs were similar to those in the main analysis for readmission and mortality at both 30 days and 365 days post hospital discharge. When we considered only HF readmissions in the main sample, we found RRs similar to the RRs for all-cause readmission in OPTIMIZE-HF (0.89 for 1-year all-cause readmission in OPTIMIZE-HF vs. 0.83 for 30-day HF readmission and 0.79 for HF readmission at 365 days in our study). A study of Medicare beneficiaries in Alabama found an association between beta blocker prescriptions and mortality, but not HF readmission or all-cause readmission \[[@pone.0233161.ref015]\]. However, this study was small (380 matched pairs) and did not take into account competing risks.

Among Medicare beneficiaries with chronic heart failure, 45% of preventable hospital admissions over a 1-year period are due to non-cardiac causes, and the presence of non-cardiac comorbidities is associated with increased risk of readmission and mortality \[[@pone.0233161.ref016]\]. Medicare beneficiaries might be readmitted for non-HF related conditions so often that beta blockers do not have a significant benefit on readmissions, even though beta blockers improve heart function \[[@pone.0233161.ref017]\]. In both OPTIMIZE-HF \[[@pone.0233161.ref018]\] and our study population \[[@pone.0233161.ref019]\], approximately half of readmissions before 30 days were cardiovascular-related. We found that 20% of readmissions were non-HF cardiovascular readmission. Although the three beta blockers we studied are preferred in HFrEF because of their HFrEF-specific benefits, the other beta blockers may have beneficial effects on other non-HF cardiovascular causes of hospitalization. This possibility could help to explain the differences in finding between our study and OPTIMIZE-HF. Increasing the number of filled beta blocker prescriptions among patients hospitalized for HFrEF might not reduce total readmission rates among typical patients with HFrEF. However, we did still observe a benefit for mortality.

Limitations and strengths {#sec010}
-------------------------

Although our study addressed gaps in our understanding of the effects of beta blockers in typical patients with HFrEF, it had limitations. First, because of the time period of our study, we were not able to assess the impact of newly recommended angiotensin receptor-neprilysin inhibitors (ARNI) or sinoatrial node modulators (i.e., ivabradine) in Medicare beneficiaries \[[@pone.0233161.ref020],[@pone.0233161.ref021]\]. Additional research with sufficient follow up time of Medicare beneficiaries using these medications will be critical for understanding these medications' population-based impact. We did not include measures of dosage, but previous studies have found that few Medicare beneficiaries with HFrEF are uptitrated on an evidence-based beta blocker within one year of discharge \[[@pone.0233161.ref022]\]. We assumed that filling a prescription for a beta blocker was a proxy for continued use for the remainder of the period of follow up, but some participants will have stopped taking the medication during follow up in response to potential side effects or new contraindications. Therefore, out estimates of benefit may be exaggerated or underestimated compared to the true benefit. Perhaps the most consequential limitation of our study was that we could not fully account for the propensity of the sickest patients with HFrEF to not receive treatment (i.e., "confounding by indication") \[[@pone.0233161.ref023]\], due to lack of access to vital signs, laboratory measures, cardiac function (e.g., ejection fraction), and patient preference in Medicare data to calculate and adjust for an appropriate risk score \[[@pone.0233161.ref024]\]. Another source of confounding could have been that patients who are more likely to be adherent to any drug regimen for HFrEF and thus have better outcomes may be more likely to fill a prescription for a beta blocker. Therefore, this analysis may overestimate the apparent benefits of beta blocker use. In particular, filling a prescription for a beta blocker shortly after discharge may be a marker of adherence to medical therapy in general, which may help explain the large apparent benefit on mortality immediately following hospitalization. Finally, even though our study targeted a more general patient population than previous RCTs of beta blockers or registry studies, we were still somewhat limited in our ability to generalize our results to all Medicare beneficiaries. Participants who were excluded from the study sample were more likely to be female, live in a nursing home, and have had a SNF stay in the year prior to hospitalization and less likely to be taking an evidence-based beta blocker, which were all expected differences given our exclusion criteria (see [S1 Table](#pone.0233161.s003){ref-type="supplementary-material"}). However, beneficiaries excluded from our analysis were also more likely to be dual-eligible for Medicare and Medicaid, have a Medicare Part D subsidy, and have a higher comorbidity burden. We therefore implicitly excluded sicker beneficiaries of lower socioeconomic status, and it is possible that these beneficiaries would have been less likely to fill a prescription for a beta blocker and have higher risk of the outcomes of interest. It is unclear whether our estimates generalize to these beneficiaries.

Strengths of our study included the use of a large and more generalizable sample of patients with HFrEF than previous studies, using claims for prescription fills, which are more proximal to medication used compared to discharge prescriptions, and using a claims-based definition of HFrEF that has a positive predictive value of 77% \[[@pone.0233161.ref025]\] m as well as using statistical methods to reduce bias including accounting for competing risks in our survival analysis models, accounting for non-proportional hazards, and using prescription fills for a beta blocker after hospitalization as a time-varying covariate.

Conclusions {#sec011}
===========

In conclusion, among Medicare beneficiaries with HFrEF, we found no evidence that evidence-based beta blocker use associated with all-cause readmission after adjusting for differences in mortality. Beta blocker use was associated with lower mortality and lower risk of HF readmission. However, in this retrospective observational study, we were unable to disentangle the effects of beta blocker use from other characteristics and behaviors such as adherence to other therapies. This adherence to other therapies may have led to overestimation of the protective associations of beta blocker use, particularly on mortality. Increasing the use of beta blockers following HFrEF hospitalization is unlikely to decrease all-cause readmissions among Medicare beneficiaries, but may reduce HF-specific readmissions and mortality.
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We look forward to receiving your revised manuscript.

Kind regards,

Hans-Peter Brunner-La Rocca, M.D.

Academic Editor
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Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. In ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study. Specifically, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3.  We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.
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a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.
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Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

5\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General comment, summary

The manuscript entitled "Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction" by Loop et al. reported from a

retrospective cohort study of beneficiaries in the Medicare 5% sample hospitalized for

HFrEF between 2007 and 2013 and were discharged alive. They compared in total 12,127 participants, the 30-day and 365-day heart failure (HF) readmission, all-cause readmission, and mortality rates between beneficiaries who filled a prescription for an evidence-based beta blocker (carvedilol, bisoprolol, and sustained-release metoprolol succinate) and those who did not after being hospitalized for HFrEF.

The main finding of the analyses (adjusted risk models) and conclusion accordingly, was that increasing the use of beta blockers following HFrEF hospitalization is unlikely to decrease all-cause readmissions among Medicare beneficiaries, but may reduce HF-specific readmissions and mortality.

In my perspective, this analysis from a large HFrEF cohort, though retrospective, is well-conducted and the results are clinically important and add to our understanding of relevant outcomes associated with evidence-based HF therapies in real-world practice, e.g. in US.

The authors also included two sensitivity analyses in their report.

The present manuscript is easy-to-follow, well written, both in wording and grammar.

The comprehensive tables and figure, respectively contribute to the clear presentation of the results and interpretation.

Major comments

1\. This retrospective cohort study is observational with its inherent limitations, although is a sample of real-world HF care in the US. The cohort, however, is not that contemporary.

2\. Definition of HFrEF is not clear, uniform, or at discretion of the physician. Although, the sample is random and for that reason, close to generalizability.

3\. Information on optimal or maximal beta-blocker doses is not provided (or lacking, not collected?); suboptimal up-titrated medication may be associated with more severe HFrEF, comorbidity burden, high age, and many other factors; and has effects on important morbidity and mortality.

4\. Confounding by indication could only be partially accounted for.

5\. Do the authors have insights or due thoughts on (substantially reported) non-presciption of beta-blockers?

6\. Differential analyses of each beta-blocker may add to our knowledge, e.g. carvedilol as additional pharmocodynamic properties.

7\. Do the authors have data on repeat hospitalizations?

8\. Do the authors have data on (CIED) device usage; which may have effects on clinical outcomes? This also goes for non-HF cardiovascular medication.

9\. How do the authors explain their finding that all-cause hospitalization is not significantly associated with filled prescription of a disease-modifying beta-blocker? In contrast to OPTIMIZE-HF, although in which all beta-blockers were taken into analysis?

10\. The latter finding is strikingly important, is even incorporated in the manuscript title, and needs more detailed clarification and discussion accordingly, and guidance for future studies.

Minor comments

1\. What definitions of anemia, atrial fibrillation and other comorbidities were used?

2\. The authors used claim for a prescription fill as a proxy for beta-blocker use by HFrEF patients; has that been validated previously?

3\. There is no certainty at all for continued use of beta-blocker, discontinuation, or intolerance, and also, no reported reasons for modified medication regimens

4\. Relatively more patients from lower socio-economic status were excluded, which may influence outcomes and also elaborated risk stratification and generalizability.

5\. The authors may describe strengths and limitations in a more separate paragraph or section at the end of Discussion, just prior to Conclusions.

6\. In Figure 1, first panel, CIs are not depicted.

Reviewer \#2: Summary:

This retrospective study investigated the effect of beta-blocker treatment in HFrEF beneficiaries in the Medicare 5% sample. For study inclusion, HFrEF patients had to have HFrEF related HF hospitalized between 2007 and 2013 and had to be alive at discharge.

Beta-blocker treatment after hospital discharge was assumed on the basis that study participants (overall 35%) filled prescription of an evidenced-based beta blocker (metoprolol, bisoprolol, carvedilol). These study participants were compared to study participants who did not fill a prescription for beta blocker treatment after hospital discharge. Outcome measure was 30 day and 365 day heart failure or all cause readmission rate, or all cause mortality. The first occurring event was always entered into the analysis. Out of 12127 beneficiaries with index hospitalization for HFrEF 30% were readmitted for HF hospitalization, 62% for any cause; 27% died within 365 days.

Filling a prescription for a beta blocker was associated with a lower HF readmission rate and a lower mortality rate but did not change the all-cause readmission rate in competing risk models.

Critique:

This retrospective analysis of data derived from U.S. medicare beneficiaries shows beneficial effects of beta-blocker treatment on heart failure readmission and mortality when study participants filled the beta blocker prescription within 0-3 day, 4-7 days, or \> 7 days. This beneficial effect was already present within the first 30 days and persisted thereafter. This observation is surprising since Kaplan-Meier curves presenting survival or the combined endpoint of survival and heart-failure related hospitalization separated only after 3 months beta blocker treatment in the MERIT-HF or the COPERNICUS trial. Likewise, separation of survival curves in the BIOSTAT-CHF study occurred only after 100 days in patients on guidelines-based medical therapy. I wonder whether this important early effect is really associated with beta blocker treatment alone and not related to overall good compliance to drug treatment in the 35% of study participants filling the prescription?

The authors should discuss why the results of this retrospective analysis are still valid in 2019. HFrEF treatment changed because of results of EMPHASIS-HF published in 2011 and the PARADIGM-HF published in 2015. Why did the authors choose to analyze the effect of beta blocker treatment on 365 days all-cause mortality in real-world patients 2007-2013?

Why did the authors decide to measure the first hospitalization independent whether it was a hospitalization for heart failure or other reason? Reason for this question is the fact that it is clear that beta-blocker treatment should reduce heart failure related-hospitalization but not hospitalization for other comorbidity. How can You exclude that the effect of beta-blocker treatment on heart failure related hospitalization was underestimated?

Why did the authors did not adjust for other heart failure drug treatment?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Roger Hullin MD

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0233161.r002

Author response to Decision Letter 0

25 Mar 2020

We have responded to the reviewer comments in the \"Response to reviewers\" file.
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Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction

PLOS ONE

Dear Dr. Loop,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

One of the reviewers was still not satisfied with the paper. This is why we internally discussed the issue. The major concern of the reviewer remains the interpretation of the early effects on mortality (within 30 days). I understand that the data do not allow to investigate the exact reason for this effect and that the interpretation remains somewhat speculative. Nevertheless, I agree with the reviewer that overall better compliance may play an important role and would like to ask you to further emphasize this possibility in your limitation and include this also in your conclusions.

On purpose, the reviewer\'s comments are not included in this mail as they do not provide additional information.

We would appreciate receiving your revised manuscript by Jun 06 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Hans-Peter Brunner-La Rocca, M.D.

Academic Editor

PLOS ONE

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Thank you very much for the opportunity to revise and resubmit our manuscript. Upon further considering of the comments from one reviewer and yourself, we whole-heartedly agree that our inability to separate the benefits of beta blockers from general adherence, especially to other therapies, is a limitation. Therefore, we have added a statement regarding this limitation in the Discussion, as well as in our Conclusions. We have reproduced both sets of text below for your convenience.

Discussion

...

Another source of confounding could have been that patients who are more likely to be adherent to any drug regimen for HFrEF and thus have better outcomes may be more likely to fill a prescription for a beta blocker. Therefore, this analysis may overestimate the apparent benefits of beta blocker use. In particular, filling a prescription for a beta blocker shortly after discharge may be a marker of adherence to medical therapy in general, which may help explain the large apparent benefit on mortality immediately following hospitalization.

Conclusions

However, in this retrospective observational study, we were unable to disentangle the effects of beta blocker use from other characteristics and behaviors such as adherence to other therapies. This adherence to other therapies may have led to overestimation of the protective associations of beta blocker use, particularly on mortality.

We very much hope these changes are satisfactory, as we would be proud to have this manuscript published in PLOS ONE.
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PONE-D-19-24254R2

Dear Dr. Loop,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Hans-Peter Brunner-La Rocca, M.D.

Academic Editor

PLOS ONE

10.1371/journal.pone.0233161.r006
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This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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PONE-D-19-24254R2

Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction

Dear Dr. Loop:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Hans-Peter Brunner-La Rocca

Academic Editor

PLOS ONE
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